XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

For the three and nine months ended September 30, 2022 and 2021, the Company had the following disaggregated revenue:

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2022   %   2021   %   2022   %   2021   % 
Telehealth revenue  $21,365,178    68%  $18,540,897    74%  $66,231,202    73%  $47,623,822    73%
WorkSimpli revenue   10,047,291    32%   6,406,302    26%   24,682,602    27%   17,835,100    27%
Total net revenue  $31,412,469    100%  $24,947,199    100%  $90,913,804    100%  $65,458,922    100%
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the in-process monthly or yearly contracts with customers and a portion attributable to the yet to be recognized initial 14-day trial period collections.

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2022   2021   2022   2021 
Beginning of period  $1,992,502   $1,381,938   $1,499,880   $916,880 
Additions   9,346,553    6,020,061    23,567,740    17,233,084 
Revenue recognized   (8,985,903)   (5,966,018)   (22,714,468)   (16,713,983)
End of period  $2,353,152   $1,435,981   $2,353,152   $1,435,981 
SUMMARY OF INVENTORY

As of September 30, 2022 and December 31, 2021, the Company’s inventory consisted of the following:

 

   September 30,   December 31, 
   2022   2021 
Finished Goods - Products  $2,829,053   $1,592,654 
Raw materials and packaging components   891,399    81,427 
Inventory reserve   (44,321)   (57,481)
Total Inventory - net  $3,676,131   $1,616,600 
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive, even though the exercise price could be less than the average market price of the common shares:

 

   September 30, 2022   September 30, 2021   September 30, 2022   September 30, 2021 
  

Three Months

Ended

  

Three Months

Ended

  

Nine Months

Ended

  

Nine Months

Ended

 
   September 30, 2022   September 30, 2021   September 30, 2022   September 30, 2021 
                 
Series B Preferred Stock   1,369,581    1,229,581    1,334,421    1,195,446 
Restricted Stock Units (RSUs)   1,830,750    996,375    1,563,000    569,417 
Stock options   4,007,698    4,170,900    4,214,609    4,193,100 
Warrants   3,859,638    3,888,438    3,859,638    3,807,899 
Potentially dilutive securities   11,067,667    10,285,294    10,971,668    9,765,862